Log in
Enquire now
‌

US Patent 10323026 Heterocyclic compound

Patent 10323026 was granted and assigned to Takeda Pharmaceutical Company on June, 2019 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors
Is a
Patent
Patent
Current Assignee
Takeda Pharmaceutical Company
Takeda Pharmaceutical Company
Date Filed
March 30, 2017
Date of Patent
June 18, 2019
Patent Application Number
15474192
Patent Citations Received
‌
US Patent 12012411 Viral replication inhibitors
0
‌
US Patent 10696632 Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
‌
US Patent 10730884 Substituted indole compound derivatives as dengue viral replication inhibitors
‌
US Patent 10765662 Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
‌
US Patent 10786484 Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
0
‌
US Patent 10913716 Substituted indoline derivatives as dengue viral replication inhibitors
‌
US Patent 10919854 Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
‌
US Patent 11053196 Substituted indoline derivatives as dengue viral replication inhibitors
‌
US Patent 11279704 Viral replication inhibitors
‌
US Patent 11702387 Substituted indoline derivatives as dengue viral replication inhibitors
0
•••
Patent Inventor Names
Shuhei Ikeda
0
Jumpei Aida
0
Masataka Murakami
0
Minoru Nakamura
0
Tomohiro Okawa
0
Yuya Oguro
0
Hidekazu Tokuhara
0
Hideyuki Sugiyama
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
10323026
Patent Primary Examiner
‌
Shawquia Jackson

Find more entities like US Patent 10323026 Heterocyclic compound

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo
By using this site, you agree to our Terms of Service.